SEC Company Response from Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Jan 10, 2020
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Jan. 10, 2020 · CIK: 0001645469 · Accession: 0001654954-20-000296
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235791
Letter
Blueprint
Monopar Therapeutics Inc.
Skokie Blvd., Suite 350
Wilmette, Illinois 60091
January 10, 2020
VIA EDGAR
US Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re: Monopar Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-235791
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 9:00 a.m., Eastern time, on January 13, 2020 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance.
Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.
Very
truly yours,
Monopar
Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm Blueprint Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 January 10, 2020 VIA EDGAR US Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-3 File No. 333-235791 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 9:00 a.m., Eastern time, on January 13, 2020 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance. Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement. Very truly yours, Monopar Therapeutics Inc. By: _/s/ Chandler D. Robinson Chandler D. Robinson Chief Executive Officer